Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2012 (2012), Article ID 145754, 12 pages
http://dx.doi.org/10.1155/2012/145754
Review Article

Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease

1Department of General Internal Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
2Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan

Received 22 June 2011; Accepted 31 August 2011

Academic Editor: Amalia Gastaldelli

Copyright © 2012 Mikako Obika and Hirofumi Noguchi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. Ratziu, S. Bellentani, H. Cortez-Pinto, C. Day, and G. Marchesini, “A position statement on NAFLD/NASH based on the EASL 2009 special conference,” Journal of Hepatology, vol. 53, no. 2, pp. 372–384, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. L. S. Szczepaniak, P. Nurenberg, D. Leonard et al., “Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population,” American Journal of Physiology, vol. 288, no. 2, pp. E462–E468, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. G. Marchesini, M. Brizi, A. M. Morselli-Labate et al., “Association of nonalcoholic fatty liver disease with insulin resistance,” American Journal of Medicine, vol. 107, no. 5, pp. 450–455, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Marceau, S. Biron, F. S. Hould et al., “Liver pathology and the metabolic syndrome X in severe obesity,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 5, pp. 1513–1517, 1999. View at Google Scholar · View at Scopus
  5. G. Marchesini, M. Brizi, G. Blanchi et al., “Nonalcoholic fatty liver disease: a feature of the metabolic syndrome,” Diabetes, vol. 50, no. 8, pp. 1844–1850, 2001. View at Google Scholar · View at Scopus
  6. “Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report,” Circulation, vol. 106, no. 25, pp. 3143–3421, 2002.
  7. A. I. Shulman and D. J. Mangelsdorf, “Retinoid X receptor heterodimers in the metabolic syndrome,” The New England Journal of Medicine, vol. 353, no. 6, pp. 604–615, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. J. R. Lewis and S. R. Mohanty, “Nonalcoholic fatty liver disease: a review and update,” Digestive Diseases and Sciences, vol. 55, no. 3, pp. 560–578, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. J. Edmison and A. J. McCullough, “Pathogenesis of non-alcoholic steatohepatitis: human data,” Clinics in Liver Disease, vol. 11, no. 1, pp. 75–104, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. A. Wieckowska and A. E. Feldstein, “Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive,” Seminars in Liver Disease, vol. 28, no. 4, pp. 386–395, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. P. Angulo, “Medical progress: nonalcoholic fatty liver disease,” The New England Journal of Medicine, vol. 346, no. 16, pp. 1221–1231, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. J. D. Browning, L. S. Szczepaniak, R. Dobbins et al., “Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity,” Hepatology, vol. 40, no. 6, pp. 1387–1395, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. J. G. Fan, J. Zhu, X. J. Li et al., “Prevalence of and risk factors for fatty liver in a general population of Shanghai, China,” Journal of Hepatology, vol. 43, no. 3, pp. 508–514, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. S. Jimba, T. Nakagami, M. Takahashi et al., “Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults,” Diabetic Medicine, vol. 22, no. 9, pp. 1141–1145, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. P. Gupte, D. Amarapurkar, S. Agal et al., “Non-alcoholic steatohepatitis in type 2 diabetes mellitus,” Journal of Gastroenterology and Hepatology, vol. 19, no. 8, pp. 854–858, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. I. R. Wanless and J. S. Lentz, “Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors,” Hepatology, vol. 12, no. 5, pp. 1106–1110, 1990. View at Publisher · View at Google Scholar · View at Scopus
  17. Z. M. Younossi, T. Gramlich, C. A. Matteoni, N. Boparai, and A. J. McCullough, “Nonalcoholic fatty liver disease in patients with type 2 diabetes,” Clinical Gastroenterology and Hepatology, vol. 2, no. 3, pp. 262–265, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. L. A. Adams, S. Harmsen, J. L. S. Sauver et al., “Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study,” American Journal of Gastroenterology, vol. 105, no. 7, pp. 1567–1573, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. G. Targher, L. Bertolini, F. Poli et al., “Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients,” Diabetes, vol. 54, no. 12, pp. 3541–3546, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Targher, C. P. Day, and E. Bonora, “Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease,” The New England Journal of Medicine, vol. 363, no. 14, pp. 1341–1350, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. N. Ghouri, D. Preiss, and N. Sattar, “Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data,” Hepatology, vol. 52, no. 3, pp. 1156–1161, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. M. Rashid and E. A. Roberts, “Nonalcoholic steatohepatitis in children,” Journal of Pediatric Gastroenterology and Nutrition, vol. 30, no. 1, pp. 48–53, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. N. D. Manton, J. Lipsett, D. J. Moore, G. P. Davidson, A. J. Bourne, and R. T. L. Couper, “Non-alcoholic steatohepatitis in children and adolescents,” Medical Journal of Australia, vol. 173, no. 9, pp. 476–479, 2000. View at Google Scholar · View at Scopus
  24. J. S. Leeds, E. M. Forman, S. Morley, A. R. Scott, S. Tesfaye, and D. S. Sanders, “Abnormal liver function tests in patients with Type 1 diabetes mellitus: prevalence, clinical correlations and underlying pathologies,” Diabetic Medicine, vol. 26, no. 12, pp. 1235–1241, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. G. Targher, L. Bertolini, R. Padovani et al., “Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes,” Journal of Hepatology, vol. 53, no. 4, pp. 713–718, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. B. A. Neuschwander-Tetri and S. H. Caldwell, “Nonalcoholic steatohepatitis: summary of an AASLD single topic conference,” Hepatology, vol. 37, no. 5, pp. 1202–1219, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. J. K. Dowman, J. W. Tomlinson, and P. N. Newsome, “Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis,” Alimentary Pharmacology and Therapeutics, vol. 33, no. 5, pp. 525–540, 2011. View at Publisher · View at Google Scholar · View at PubMed
  28. B. W. Smith and L. A. Adams, “Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment,” Nature Reviews Endocrinology, vol. 7, no. 8, pp. 456–465, 2011. View at Google Scholar
  29. D. M. Torres and S. A. Harrison, “Diagnosis and therapy of nonalcoholic steatohepatitis,” Gastroenterology, vol. 134, no. 6, pp. 1682–1698, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. P. Mofrad, M. J. Contos, M. Haque et al., “Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values,” Hepatology, vol. 37, no. 6, pp. 1286–1292, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. A. L. Fracanzani, L. Valenti, E. Bugianesi et al., “Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes,” Hepatology, vol. 48, no. 3, pp. 792–798, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. D. S. Pratt and M. M. Kaplan, “Evaluation of abnormal liver-enzyme results in asymptomatic patients,” The New England Journal of Medicine, vol. 342, no. 17, pp. 1266–1271, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. P. Angulo, J. C. Keach, K. P. Batts, and K. D. Lindor, “Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis,” Hepatology, vol. 30, no. 6, pp. 1356–1362, 1999. View at Google Scholar · View at Scopus
  34. R. Haring, H. Wallaschofski, M. Nauck, M. Dörr, S. E. Baumeister, and H. Völzke, “Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels,” Hepatology, vol. 50, no. 5, pp. 1403–1411, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. C. E. Ruhl and J. E. Everhart, “Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population,” Gastroenterology, vol. 136, no. 2, pp. 477–485, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. V. Tahan, B. Canbakan, H. Balci et al., “Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk,” Hepato-Gastroenterology, vol. 55, no. 85, pp. 1433–1438, 2008. View at Google Scholar · View at Scopus
  37. M. W. Pantsari and S. A. Harrison, “Nonalcoholic fatty liver disease presenting with an isolated elevated alkaline phosphatase,” Journal of Clinical Gastroenterology, vol. 40, no. 7, pp. 633–635, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Sumida, T. Yoshikawa, and T. Okanoue, “Role of hepatic iron in non-alcoholic steatohepatitis,” Hepatology Research, vol. 39, no. 3, pp. 213–222, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. A. M. Diehl, “Nonalcoholic fatty liver disease: implications for alcoholic liver disease pathogenesis,” Alcoholism, vol. 25, no. 5, pp. 8S–14S, 2001. View at Google Scholar · View at Scopus
  40. A. M. Diehl, “Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease,” Clinics in Liver Disease, vol. 8, no. 3, pp. 619–638, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. S. Abiru, K. Migita, Y. Maeda et al., “Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis,” Liver International, vol. 26, no. 1, pp. 39–45, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. A. E. Feldstein, N. W. Werneburg, A. Canbay et al., “Free fatty acids promote hepatic lipotoxicity by stimulating TNF-α expression via a lysosomal pathway,” Hepatology, vol. 40, no. 1, pp. 185–194, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. J. M. Hui, A. Hodge, G. C. Farrell, J. G. Kench, A. Kriketos, and J. George, “Beyond insulin resistance in NASH: TNF-α or adiponectin?” Hepatology, vol. 40, no. 1, pp. 46–54, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. Z. Li, S. Yang, H. Lin et al., “Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease,” Hepatology, vol. 37, no. 2, pp. 343–350, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. H. Xu, K. Teoman Uysal, J. David Becherer, P. Arner, and G. S. Hotamisligil, “Altered tumor necrosis factor-α (TNF-α) processing in adipocytes and increased expression of transmembrane TNF-α in obesity,” Diabetes, vol. 51, no. 6, pp. 1876–1883, 2002. View at Google Scholar · View at Scopus
  46. A. Xu, Y. Wang, H. Keshaw, L. Y. Xu, K. S. L. Lam, and G. J. S. Cooper, “The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice,” The Journal of Clinical Investigation, vol. 112, no. 1, pp. 91–100, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. J. Crespo, A. Cayoen, P. Fernendez-Gil et al., “Gene expression of tumor necrosis factor α and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients,” Hepatology, vol. 34, no. 6, pp. 1158–1163, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. M. Shimada, H. Kawahara, K. Ozaki et al., “Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis,” American Journal of Gastroenterology, vol. 102, no. 9, pp. 1931–1938, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. M. Argentou, D. G. Tiniakos, M. Karanikolas et al., “Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery,” Obesity Surgery, vol. 19, no. 9, pp. 1313–1323, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. V. A. Arvaniti, K. C. Thomopoulos, A. Tsamandas et al., “Serum adiponectin levels in different types of non alcoholic liver disease. Correlation with steatosis, necroinflammation and fibrosis,” Acta Gastro-Enterologica Belgica, vol. 71, no. 4, pp. 355–360, 2008. View at Google Scholar · View at Scopus
  51. M. Yoneda, H. Mawatari, K. Fujita et al., “High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH,” Journal of Gastroenterology, vol. 42, no. 7, pp. 573–582, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. G. Targher, “Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease,” Journal of Hepatology, vol. 45, no. 6, pp. 879–881, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. J. M. Hui, G. C. Farrell, J. G. Kench, and J. George, “High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD,” Hepatology, vol. 39, no. 5, pp. 1458–1459, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. A. Wieckowska, B. G. Papouchado, Z. Li, R. Lopez, N. N. Zein, and A. E. Feldstein, “Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis,” American Journal of Gastroenterology, vol. 103, no. 6, pp. 1372–1379, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. G. Tarantino, P. Conca, F. Pasanisi et al., “Could inflammatory markers help diagnose nonalcoholic steatohepatitis?” European Journal of Gastroenterology and Hepatology, vol. 21, no. 5, pp. 504–511, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. M. Lemoine, V. Ratziu, M. Kim et al., “Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease,” Liver International, vol. 29, no. 9, pp. 1431–1438, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. N. Chalasani, D. W. Crabb, O. W. Cummings et al., “Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis?” American Journal of Gastroenterology, vol. 98, no. 12, pp. 2771–2776, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. A. Uygun, A. Kadayifci, Z. Yesilova et al., “Serum leptin levels in patients with nonalcoholic steatohepatitis,” American Journal of Gastroenterology, vol. 95, no. 12, pp. 3584–3589, 2000. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Chitturi, G. Farrell, L. Frost et al., “Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?” Hepatology, vol. 36, no. 2, pp. 403–409, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. J. W. Haukeland, J. K. Damås, Z. Konopski et al., “Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2,” Journal of Hepatology, vol. 44, no. 6, pp. 1167–1174, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. A. Suzuki, P. Angulo, J. Lymp, D. Li, S. Satomura, and K. Lindor, “Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease,” Liver International, vol. 25, no. 4, pp. 779–786, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. A. Parés, R. Deulofeu, A. Giménez et al., “Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis,” Hepatology, vol. 24, no. 6, pp. 1399–1403, 1996. View at Publisher · View at Google Scholar · View at Scopus
  63. H. Sakugawa, T. Nakayoshi, K. Kobashigawa et al., “Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease,” World Journal of Gastroenterology, vol. 11, no. 2, pp. 255–259, 2005. View at Google Scholar · View at Scopus
  64. M. Yoneda, H. Mawatari, K. Fujita et al., “Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage,” Journal of Gastroenterology, vol. 42, no. 5, pp. 375–381, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. V. N. dos Santos, M. M. B. Leite-Mór, M. Kondo et al., “Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease,” Brazilian Journal of Medical and Biological Research, vol. 38, no. 5, pp. 747–753, 2005. View at Google Scholar · View at Scopus
  66. C. P. M. S. Oliveira, L. C. Da Costa Gayotto, C. Tatai et al., “Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline-deficient diet,” Journal of Cellular and Molecular Medicine, vol. 6, no. 3, pp. 399–406, 2002. View at Google Scholar · View at Scopus
  67. T. Roskams, S. Q. Yang, A. Koteish et al., “Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease,” American Journal of Pathology, vol. 163, no. 4, pp. 1301–1311, 2003. View at Google Scholar · View at Scopus
  68. A. Wieckowska, A. J. McCullough, and A. E. Feldstein, “Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future,” Hepatology, vol. 46, no. 2, pp. 582–589, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. D. Bonnefont-Rousselot, V. Ratziu, P. Giral, F. Charlotte, I. Beucler, and T. Poynard, “Blood oxidative stress markers are unreliable markers of hepatic steatosis,” Alimentary Pharmacology and Therapeutics, vol. 23, no. 1, pp. 91–98, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. N. Chalasani, M. A. Deeg, and D. W. Crabb, “Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis,” American Journal of Gastroenterology, vol. 99, no. 8, pp. 1497–1502, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. Y. Sumida, T. Nakashima, T. Yoh et al., “Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease,” Journal of Hepatology, vol. 38, no. 1, pp. 32–38, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. T. Nakashima, Y. Sumida, M. Furutani et al., “Elevation of serum thioredoxin levels in patients with nonalcoholic steatohepatitis,” Hepatology Research, vol. 33, no. 2, pp. 135–137, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. A. E. Feldstein, A. Canbay, P. Angulo et al., “Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis,” Gastroenterology, vol. 125, no. 2, pp. 437–443, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. A. E. Feldstein, A. Canbay, M. E. Guicciardi, H. Higuchi, S. F. Bronk, and G. J. Gores, “Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice,” Journal of Hepatology, vol. 39, no. 6, pp. 978–983, 2003. View at Publisher · View at Google Scholar · View at Scopus
  75. A. E. Feldstein and G. J. Gores, “Apoptosis in alcoholic and nonalcoholic steatohepatitis,” Frontiers in Bioscience, vol. 10, no. 3, pp. 3093–3099, 2005. View at Google Scholar · View at Scopus
  76. A. E. Feldstein, N. W. Werneburg, Z. Li, S. F. Bronk, and G. J. Gores, “Bax inhibition protects against free fatty acid-induced lysosomal permeabilization,” American Journal of Physiology, vol. 290, no. 6, pp. G1339–G1346, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. Z. Li, M. Berk, T. M. McIntyre, G. J. Gores, and A. E. Feldstein, “The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity,” Hepatology, vol. 47, no. 5, pp. 1495–1503, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. A. Wieckowska, N. N. Zein, L. M. Yerian, A. R. Lopez, A. J. McCullough, and A. E. Feldstein, “In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease,” Hepatology, vol. 44, no. 1, pp. 27–33, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. A. E. Feldstein, A. Wieckowska, A. R. Lopez, Y. C. Liu, N. N. Zein, and A. J. McCullough, “Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study,” Hepatology, vol. 50, no. 4, pp. 1072–1078, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. R. Malik, M. Chang, K. Bhaskar et al., “The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease,” Journal of Gastroenterology and Hepatology, vol. 24, no. 4, pp. 564–568, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. R. R. Mitry, R. De Bruyne, A. Quaglia, R. D. Hughes, and A. Dhawan, “Noninvasive diagnosis of nonalcoholic fatty liver disease using serum biomarkers,” Hepatology, vol. 46, no. 6, pp. 2047–2048, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. G. V. Papatheodoridis, E. Hadziyannis, E. Tsochatzis et al., “Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic fatty liver disease,” Journal of Clinical Gastroenterology, vol. 44, no. 4, pp. e87–e95, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. Y. Yilmaz, E. Dolar, E. Ulukaya et al., “Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis,” World Journal of Gastroenterology, vol. 13, no. 6, pp. 837–844, 2007. View at Google Scholar · View at Scopus
  84. M. Tsutsui, N. Tanaka, M. Kawakubo et al., “Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels,” Journal of Clinical Gastroenterology, vol. 44, no. 6, pp. 440–447, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. Y. Yilmaz, “Systematic review: caspase-cleaved fragments of cytokeratin 18—the promises and challenges of a biomarker for chronic liver disease,” Alimentary Pharmacology and Therapeutics, vol. 30, no. 11-12, pp. 1103–1109, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. D. L. Diab, L. Yerian, P. Schauer et al., “Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients,” Clinical Gastroenterology and Hepatology, vol. 6, no. 11, pp. 1249–1254, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  87. M. Gulsen, Z. Yesilova, S. Bagci et al., “Elevated plasma homocysteine concentrations as a predictor of steatohepatitis in patients with non-alcoholic fatty liver disease,” Journal of Gastroenterology and Hepatology, vol. 20, no. 9, pp. 1448–1455, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. H. Kayadibi, M. Gültepe, B. Yasar et al., “Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease: a surrogate marker to distinguish steatohepatitis from simple steatosis,” Digestive Diseases and Sciences, vol. 54, no. 8, pp. 1764–1771, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  89. M. Yoneda, T. Uchiyama, S. Kato et al., “Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH),” BMC Gastroenterology, vol. 8, article 53, 2008. View at Publisher · View at Google Scholar · View at PubMed
  90. G. Tarantino, P. Conca, A. Coppola, R. Vecchione, and G. Di Minno, “Serum concentrations of the tissue polypeptide specific antigen in patients suffering from non-alcoholic steatohepatitis,” The European Journal of Clinical Investigation, vol. 37, no. 1, pp. 48–53, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  91. A. Kotronen, M. Peltonen, A. Hakkarainen et al., “Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors,” Gastroenterology, vol. 137, no. 3, pp. 865–872, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  92. G. Bedogni, S. Bellentani, L. Miglioli et al., “The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population,” BMC Gastroenterology, vol. 6, article 33, 2006. View at Publisher · View at Google Scholar · View at PubMed
  93. G. Bedogni, H. S. Kahn, S. Bellentani, and C. Tiribelli, “A simple index of lipid overaccumulation is a good marker of liver steatosis,” BMC Gastroenterology, vol. 10, article 98, 2010. View at Publisher · View at Google Scholar · View at PubMed
  94. S. Petta, M. Amato, D. Cabibi et al., “Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1,” Hepatology, vol. 52, no. 5, pp. 1543–1552, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  95. J. B. Dixon, P. S. Bhathal, and P. E. O'Brien, “Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese,” Gastroenterology, vol. 121, no. 1, pp. 91–100, 2001. View at Google Scholar · View at Scopus
  96. N. A. Palekar, R. Naus, S. P. Larson, J. Ward, and S. A. Harrison, “Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease,” Liver International, vol. 26, no. 2, pp. 151–156, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  97. P. M. Gholam, L. Flancbaum, J. T. MacHan, D. A. Charney, and D. P. Kotler, “Nonalcoholic fatty liver disease in severely obese subjects,” American Journal of Gastroenterology, vol. 102, no. 2, pp. 399–408, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  98. T. Poynard, V. Ratziu, F. Charlotte et al., “Diagnostic value of biochemical markers (Nash Test) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease,” BMC Gastroenterology, vol. 6, article 34, 2006. View at Publisher · View at Google Scholar · View at PubMed
  99. V. Ratziu, J. Massard, F. Charlotte et al., “Diagnostic value of biochemical markers (Fibro Test-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease,” BMC Gastroenterology, vol. 6, article 6, 2006. View at Publisher · View at Google Scholar · View at PubMed
  100. P. Angulo, J. M. Hui, G. Marchesini et al., “The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD,” Hepatology, vol. 45, no. 4, pp. 846–854, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  101. S. McPherson, S. F. Stewart, E. Henderson, A. D. Burt, and C. P. Day, “Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease,” Gut, vol. 59, no. 9, pp. 1265–1269, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  102. P. Calès, F. Lainé, J. Boursier et al., “Comparison of blood tests for liver fibrosis specific or not to NAFLD,” Journal of Hepatology, vol. 50, no. 1, pp. 165–173, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  103. G. Musso, R. Gambino, M. Cassader, and G. Pagano, “Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity,” Annals of Medicine. In press.
  104. W. M. C. Rosenberg, M. Voelker, R. Thiel et al., “Serum markers detect the presence of liver fibrosis: a cohort study,” Gastroenterology, vol. 127, no. 6, pp. 1704–1713, 2004. View at Publisher · View at Google Scholar · View at Scopus
  105. I. N. Guha, J. Parkes, P. Roderick et al., “Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers,” Hepatology, vol. 47, no. 2, pp. 455–460, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  106. S. A. Harrison, D. Oliver, H. L. Arnold, S. Gogia, and B. A. Neuschwander-Tetri, “Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease,” Gut, vol. 57, no. 10, pp. 1441–1447, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  107. G. Ruffillo, E. Fassio, E. Alvarez et al., “Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease,” Journal of Hepatology, vol. 54, no. 1, pp. 160–163, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  108. C. T. Wai, J. K. Greenson, R. J. Fontana et al., “A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C,” Hepatology, vol. 38, no. 2, pp. 518–526, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  109. A. Loaeza-del-Castillo, F. Paz-Pineda, E. Oviedo-Cárdenas, F. Sánchez-Ávila, and F. Vargas-Vorácková, “AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis,” Annals of Hepatology, vol. 7, no. 4, pp. 350–357, 2008. View at Google Scholar · View at Scopus
  110. H. Fujii, M. Enomoto, W. Fukushima et al., “Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis,” Journal of Gastroenterology, vol. 44, no. 6, pp. 608–614, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  111. A. L. B. Williams and J. H. Hoofnagle, “Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis,” Gastroenterology, vol. 95, no. 3, pp. 734–739, 1988. View at Google Scholar · View at Scopus
  112. B. A. Neuschwander-Tetri, J. M. Clark, N. M. Bass et al., “Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease,” Hepatology, vol. 52, no. 3, pp. 913–924, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  113. A. Vallet-Pichard, V. Mallet, B. Nalpas et al., “FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest,” Hepatology, vol. 46, no. 1, pp. 32–36, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  114. A. G. Shah, A. Lydecker, K. Murray, B. N. Tetri, M. J. Contos, and A. J. Sanyal, “Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease,” Clinical Gastroenterology and Hepatology, vol. 7, no. 10, pp. 1104–1112, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  115. P. Calès, F. Oberti, S. Michalak et al., “A novel panel of blood markers to assess the degree of liver fibrosis,” Hepatology, vol. 42, no. 6, pp. 1373–1381, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  116. S. Saadeh, Z. M. Younossi, E. M. Remer et al., “The utility of radiological imaging in nonalcoholic fatty liver disease,” Gastroenterology, vol. 123, no. 3, pp. 745–750, 2002. View at Publisher · View at Google Scholar · View at Scopus
  117. J. A. Marrero, R. J. Fontana, G. L. Su, H. S. Conjeevaram, D. M. Emick, and A. S. Lok, “NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States,” Hepatology, vol. 36, no. 6, pp. 1349–1354, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  118. H. Osawa and Y. Mori, “Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes,” Journal of Clinical Ultrasound, vol. 24, no. 1, pp. 25–29, 1996. View at Publisher · View at Google Scholar · View at Scopus
  119. A. J. Sanyal, “AGA technical review on nonalcoholic fatty liver disease,” Gastroenterology, vol. 123, no. 5, pp. 1705–1725, 2002. View at Google Scholar · View at Scopus
  120. B. Palmentieri, I. de Sio, V. La Mura et al., “The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis,” Digestive and Liver Disease, vol. 38, no. 7, pp. 485–489, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  121. S. Strauss, E. Gavish, P. Gottlieb, and L. Katsnelson, “Interobserver and intraobserver variability in the sonographic assessment of fatty liver,” American Journal of Roentgenology, vol. 189, no. 6, pp. W320–W323, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  122. C. K. Ryan, L. A. Johnson, B. I. Germin, and A. Marcos, “One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation,” Liver Transplantation, vol. 8, no. 12, pp. 1114–1122, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  123. C. C. Mottin, M. Moretto, A. V. Padoin et al., “The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients,” Obesity Surgery, vol. 14, no. 5, pp. 635–637, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  124. H. Iijima, F. Moriyasu, K. Tsuchiya et al., “Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis,” Hepatology Research, vol. 37, no. 9, pp. 722–730, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  125. H. Iijima, F. Moriyasu, T. Miyahara, and K. Yanagisawa, “Ultrasound contrast agent, Levovist microbubbles are phagocytosed by Kupffer cells-In vitro and in vivo studies,” Hepatology Research, vol. 35, no. 4, pp. 235–237, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  126. J. E. Jacobs, B. A. Birnbaum, M. A. Shapiro et al., “Diagnostic criteria for fatty infiltration of the liver on contrast- enhanced helical CT,” American Journal of Roentgenology, vol. 171, no. 3, pp. 659–664, 1998. View at Google Scholar · View at Scopus
  127. J. Piekarski, H. I. Goldberg, and S. A. Royal, “Difference between liver and spleen CT numbers in the normal adult: its usefulness in predicting the presence of diffuse liver disease,” Radiology, vol. 137, no. 3, pp. 727–729, 1980. View at Google Scholar · View at Scopus
  128. Y. Kodama, C. S. Ng, T. T. Wu et al., “Comparison of CT methods for determining the fat content of the liver,” American Journal of Roentgenology, vol. 188, no. 5, pp. 1307–1312, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  129. S. H. Park, P. N. Kim, K. W. Kim et al., “Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment,” Radiology, vol. 239, no. 1, pp. 105–112, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  130. C. Ricci, R. Longo, E. Gioulis et al., “Noninvasive in vivo quantitative assessment of fat content in human liver,” Journal of Hepatology, vol. 27, no. 1, pp. 108–113, 1997. View at Publisher · View at Google Scholar · View at Scopus
  131. O. W. Hamer, D. A. Aguirre, G. Casola, and C. B. Sirlin, “Imaging features of perivascular fatty infiltration of the liver: initial observations,” Radiology, vol. 237, no. 1, pp. 159–169, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  132. S. M. Mazhar, M. Shiehmorteza, and C. B. Sirlin, “Noninvasive assessment of hepatic steatosis,” Clinical Gastroenterology and Hepatology, vol. 7, no. 2, pp. 135–140, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  133. N. F. Schwenzer, F. Springer, C. Schraml, N. Stefan, J. Machann, and F. Schick, “Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance,” Journal of Hepatology, vol. 51, no. 3, pp. 433–445, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  134. M. H. Mendler, P. Bouillet, A. L. Sidaner et al., “Dual-energy CT in the diagnosis and quantification of fatty liver: limited clinical value in comparison to ultrasound scan and single-energy CT, with special reference to iron overload,” Journal of Hepatology, vol. 28, no. 5, pp. 785–794, 1998. View at Publisher · View at Google Scholar · View at Scopus
  135. M. Fishbein, F. Castro, S. Cheruku et al., “Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound,” Journal of Clinical Gastroenterology, vol. 39, no. 7, pp. 619–625, 2005. View at Publisher · View at Google Scholar · View at Scopus
  136. R. Longo, P. Pollesello, C. Ricci et al., “Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis,” Journal of Magnetic Resonance Imaging, vol. 5, no. 3, pp. 281–285, 1995. View at Google Scholar · View at Scopus
  137. M. Yoneda, K. Fujita, M. Inamori et al., “Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD),” Gut, vol. 56, no. 9, pp. 1330–1331, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  138. V. W. S. Wong, J. Vergniol, G. L. H. Wong et al., “Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease,” Hepatology, vol. 51, no. 2, pp. 454–462, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  139. S. G. Hübscher, “Histological assessment of non-alcoholic fatty liver disease,” Histopathology, vol. 49, no. 5, pp. 450–465, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  140. J. P. Ong and Z. M. Younossi, “Approach to the diagnosis and treatment of nonalcoholic fatty liver disease,” Clinics in Liver Disease, vol. 9, no. 4, pp. 617–634, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  141. L. A. Adams and P. Angulo, “Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease,” Clinics in Liver Disease, vol. 11, no. 1, pp. 25–35, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  142. M. M. Van Ness and A. M. Diehl, “Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes?” Annals of Internal Medicine, vol. 111, no. 6, pp. 473–478, 1989. View at Google Scholar · View at Scopus
  143. M. K. Oh, J. Winn, and F. Poordad, “Review article: diagnosis and treatment of non-alcoholic fatty liver disease,” Alimentary Pharmacology and Therapeutics, vol. 28, no. 5, pp. 503–522, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  144. E. M. Brunt, C. G. Janney, A. M. Di Bisceglie, B. A. Neuschwander-Tetri, and B. R. Bacon, “Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions,” American Journal of Gastroenterology, vol. 94, no. 9, pp. 2467–2474, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  145. A. J. Sanyal, C. Campbell-Sargent, F. Mirshahi et al., “Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities,” Gastroenterology, vol. 120, no. 5, pp. 1183–1192, 2001. View at Google Scholar · View at Scopus
  146. L. A. Adams, J. F. Lymp, J. S. Sauver et al., “The natural history of nonalcoholic fatty liver disease: a population-based cohort study,” Gastroenterology, vol. 129, no. 1, pp. 113–121, 2005. View at Publisher · View at Google Scholar · View at Scopus
  147. S. H. Caldwell, D. H. Oelsner, J. C. Iezzoni, E. E. Hespenheide, E. H. Battle, and C. J. Driscoll, “Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease,” Hepatology, vol. 29, no. 3, pp. 664–669, 1999. View at Google Scholar · View at Scopus
  148. E. E. Powell, W. G. E. Cooksley, R. Hanson, J. Searle, J. W. Halliday, and L. W. Powell, “The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years,” Hepatology, vol. 11, no. 1, pp. 74–80, 1990. View at Google Scholar · View at Scopus
  149. A. Poonawala, S. P. Nair, and P. J. Thuluvath, “Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study,” Hepatology, vol. 32, no. 4, pp. 689–692, 2000. View at Google Scholar · View at Scopus
  150. E. Bugianesi, “Review article: steatosis, the metabolic syndrome and cancer,” Alimentary Pharmacology and Therapeutics, Supplement, vol. 22, no. 2, pp. 40–43, 2005. View at Google Scholar · View at Scopus
  151. R. E. Bullock, A. M. Zaitoun, G. P. Aithal, S. D. Ryder, I. J. Beckingham, and D. N. Lobo, “Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma,” Journal of Hepatology, vol. 41, no. 4, pp. 685–686, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  152. V. Paradis, S. Zalisnski, E. Chelbi et al., “Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liverfibrosis: a pathological analysis,” Hepatology, vol. 49, no. 3, pp. 851–859, 2009. View at Publisher · View at Google Scholar · View at PubMed
  153. S. A. Harrison, E. M. Brunt, Z. D. Goodman, and A. M. Di Bisceglie, “Diabetic hepatosclerosis: diabetic microangiopathy of the liver,” Archives of Pathology and Laboratory Medicine, vol. 130, no. 1, pp. 27–32, 2006. View at Google Scholar · View at Scopus
  154. D. E. Kleiner, E. M. Brunt, M. Van Natta et al., “Design and validation of a histological scoring system for nonalcoholic fatty liver disease,” Hepatology, vol. 41, no. 6, pp. 1313–1321, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  155. E. M. Brunt, D. E. Kleiner, L. A. Wilson, P. Belt, and B. A. Neuschwander-Tetri, “Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings,” Hepatology, vol. 53, no. 3, pp. 810–820, 2011. View at Publisher · View at Google Scholar · View at PubMed
  156. V. Ratziu, F. Charlotte, A. Heurtier et al., “Sampling variability of liver biopsy in nonalcoholic fatty liver disease,” Gastroenterology, vol. 128, no. 7, pp. 1898–1906, 2005. View at Publisher · View at Google Scholar · View at Scopus
  157. D. J. Janiec, E. R. Jacobson, A. Freeth, L. Spaulding, and H. Blaszyk, “Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies,” Obesity Surgery, vol. 15, no. 4, pp. 497–501, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  158. Z. M. Younossi, T. Gramlich, C. L. Yao et al., “Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations,” Modern Pathology, vol. 11, no. 6, pp. 560–565, 1998. View at Google Scholar · View at Scopus